Clinical insights into the genomic landscape of ESR1-mutated breast cancer and implications for treatment decision-making: a large-scale analysis of 6,162 patients
- 1Department of Oncology, Shantou Central Hospital, Shantou, China
- 2State Key Laboratory of Neurology and Oncology Drug Development, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China
- 3State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostic Technology Co., Ltd, Nanjing, China
Abstract
Estrogen receptor 1 (ESR1) mutations are key drivers of endocrine resistance in hormone receptor–positive breast cancer. However, their genomic spectrum, co-mutation landscape, and prognostic relevance in real-world populations remain insufficiently characterized. This study aimed to define the distribution and clinical implications of ESR1 mutations by integrating commercial genomic testing data with the MSK public cohort. Collect genomic data from breast cancer patients in the Simceredx Cohort and the MSK 2024 Cohort to evaluate ESR1 mutation frequency, domain distribution, pathogenicity classification, co-mutation pathways, and mutation feature tags. Compare Tumor Mutation Burden (TMB) differences between ESR1-mutant and wild-type tumors, and evaluate survival prognosis in the MSK cohort. Summarize potential actionable targets and drug evidence levels based on OncoKB annotations. The ESR1 mutation rates in the two cohorts were 5.7% and 6.3%, with mutations highly enriched in the ligand-binding domain. The majority of variants were classified as likely pathogenic (LP)/ pathogenic (P) (> 98%) and predominantly represented gain-of-function missense mutations. ESR1-mutant tumors exhibited a co-mutation axis centered on TP53, PIK3CA, and GATA3, accompanied by differential enrichment in MAPK, PI3K, and DDR pathways. ESR1 mutant tumors with significantly elevated overall TMB (P ≤ 0.003). In the MSK cohort, ESR1 mutation was associated with markedly worse overall survival (HR = 2.29). Drug evidence indicates that selective estrogen receptor degraders (SERDs) provide Level 1 evidence-based support for most mutations. This study reveals the domain specificity and co-mutation background of ESR1 mutations in breast cancer, supporting its potential role in endocrine resistance stratification and providing genomic evidence relevant to SERD-directed therapeutic development.
Related
- Obesity prevalence and management insights using Adipoview a real time clinical obesity landscape indicator based on a population study
- Development and usability testing of a machine learning clinical decision support tool for suggesting etiologies and treatment of clinical deterioration
- Lipoprotein(a) and Plaque Vulnerability: Mechanistic Insights, Imaging Evidence, and Clinical Implications
- GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers
- Right and Left Bundle Branch Block in the General Population: Structural Heart Findings, Clinical and Prognostic Implications: Insights from the Hamburg City Health Study
BibTeX
@article{xie2026clinical,
title = {{Clinical insights into the genomic landscape of ESR1-mutated breast cancer and implications for treatment decision-making: a large-scale analysis of 6,162 patients}},
author = {Linhao Xie and Mengxiao Wang and Minghui Ge and Xing Zhang and Qin Zhang and Dongsheng Chen and Canfeng Lin},
journal = {Clinical and Experimental Medicine},
year = {2026},
month = aug,
doi = {10.1007/s10238-026-02244-x},
url = {https://doi.org/10.1007/s10238-026-02244-x},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Clinical insights into the genomic landscape of ESR1-mutated breast cancer and implications for treatment decision-making: a large-scale analysis of 6,162 patients
AU - Linhao Xie
AU - Mengxiao Wang
AU - Minghui Ge
AU - Xing Zhang
AU - Qin Zhang
AU - Dongsheng Chen
AU - Canfeng Lin
PY - 2026
DA - 2026/08/06
JO - Clinical and Experimental Medicine
DO - 10.1007/s10238-026-02244-x
UR - https://doi.org/10.1007/s10238-026-02244-x
AB - Estrogen receptor 1 (ESR1) mutations are key drivers of endocrine resistance in hormone receptor–positive breast cancer. However, their genomic spectrum, co-mutation landscape, and prognostic relevance in real-world populations remain insufficiently characterized. This study aimed to define the distribution and clinical implications of ESR1 mutations by integrating commercial genomic testing data with the MSK public cohort. Collect genomic data from breast cancer patients in the Simceredx Cohort and the MSK 2024 Cohort to evaluate ESR1 mutation frequency, domain distribution, pathogenicity classification, co-mutation pathways, and mutation feature tags. Compare Tumor Mutation Burden (TMB) differences between ESR1-mutant and wild-type tumors, and evaluate survival prognosis in the MSK cohort. Summarize potential actionable targets and drug evidence levels based on OncoKB annotations. The ESR1 mutation rates in the two cohorts were 5.7% and 6.3%, with mutations highly enriched in the ligand-binding domain. The majority of variants were classified as likely pathogenic (LP)/ pathogenic (P) (> 98%) and predominantly represented gain-of-function missense mutations. ESR1-mutant tumors exhibited a co-mutation axis centered on TP53, PIK3CA, and GATA3, accompanied by differential enrichment in MAPK, PI3K, and DDR pathways. ESR1 mutant tumors with significantly elevated overall TMB (P ≤ 0.003). In the MSK cohort, ESR1 mutation was associated with markedly worse overall survival (HR = 2.29). Drug evidence indicates that selective estrogen receptor degraders (SERDs) provide Level 1 evidence-based support for most mutations. This study reveals the domain specificity and co-mutation background of ESR1 mutations in breast cancer, supporting its potential role in endocrine resistance stratification and providing genomic evidence relevant to SERD-directed therapeutic development.
SN - 1591-8890
SN - 1591-9528
ER -